Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein
about
Crystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivoCharacterization of a late entry event in the replication cycle of human immunodeficiency virus type 2The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent.CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry.HIV-2 neutralization by intact V3-specific Fab fragments.Retinoschisin is linked to retinal Na/K-ATPase signaling and localization
P2860
Q27667679-9FAE3F8A-7C4E-49D1-88AB-C261AE8394FEQ33591409-2D5CB62A-684E-4B2B-A43A-E7DC8AB620E6Q33809419-9C51853B-CE0B-4C21-80F5-630DCA3A8365Q34290973-2C50C3C3-7F91-4072-8417-44F2BF5207CCQ34611466-F317A09A-4C46-49F3-91B0-1D9EFC8DDBB4Q35898388-33CE7BB3-2D6A-444E-BFEF-DBCE95814D48Q37250087-DCA00AC3-953F-4241-A492-D2CB548A3DC3Q39551124-34FD9262-2C5F-44FC-A7D6-04AB182BA8DDQ39603745-D2199136-99D8-44D9-9C0A-A784F4C68213Q39878225-5C850D56-7750-4FD9-9C23-94279FDC8675Q39878344-991061A1-841A-4F0D-9C08-8B1C7296710FQ39879869-07607935-5FB1-4719-A976-F6DB123C84F1Q41823383-B8484B70-EFDD-4F3B-B94A-638C211DBF48Q42338638-1A2F301B-BFBA-4977-99C3-9D202183298B
P2860
Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Location, exposure, and conser ...... y virus type 2 SU glycoprotein
@en
Location, exposure, and conser ...... virus type 2 SU glycoprotein.
@nl
type
label
Location, exposure, and conser ...... y virus type 2 SU glycoprotein
@en
Location, exposure, and conser ...... virus type 2 SU glycoprotein.
@nl
prefLabel
Location, exposure, and conser ...... y virus type 2 SU glycoprotein
@en
Location, exposure, and conser ...... virus type 2 SU glycoprotein.
@nl
P2093
P2860
P1433
P1476
Location, exposure, and conser ...... y virus type 2 SU glycoprotein
@en
P2093
P2860
P304
P407
P577
1996-07-01T00:00:00Z